Administrative Core
Administrative Core
批准号:
7672104
负责人:
HERBERT W VIRGIN
金额:
$47.97万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-09 至 2014-02-28
关键词:
AddressAnthrax diseaseAreaBasic ScienceBiologicalBioterrorismBudgetsChildClinicalClinical ResearchCollaborationsCommitCommunitiesComplexCore FacilityCountryDNA VirusesDengueDiagnosticDisaster PlanningEmergency SituationEmerging Communicable DiseasesEventExtramural ActivitiesFaceFundingGenerationsGoalsGovernmentHealthImmunologyIndividualInfectious Diseases ResearchInstitutionInternationalIowaKansasLaboratoriesLeadLeadershipLinkLung diseasesMeasuresMissionMissouriNational Institute of Allergy and Infectious DiseaseNebraskaOhioPathogenesisPneumonic PlaguePolyomavirusPoxviridaeProcessPublic HealthRNAResearchResearch DesignResearch InfrastructureResearch InstituteResearch PersonnelResearch SupportResourcesSaintsScientistSeminalServicesTerrorismTherapeuticTrainingTraining ProgramsTranslational ResearchTranslationsUnited StatesUnited States National Institutes of HealthUnited States Public Health ServiceUniversitiesUrsidae FamilyVaccinesVirusWashingtonWest Nile virusWorkauthoritybiodefensecareerdesigninterestinvestigator trainingmicrobialnew therapeutic targetnovel diagnosticsnovel therapeuticspathogenprogramspublic health researchresponseweapons
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Introduction: The events of September 11, 2001, and the deliberate bioterrorism attack with anthrax that
followed, led to profound changes in the biologic research and public health agenda of the United States. The
recognition that the United States was vulnerable to international terrorism, and the tremendous impact that a
relatively limited biologic weapons attack had on the nation, resulted in major changes in the research focus of
government, academic, and commercial entities. Ml AID understood that the United States lacked the research
capacity and infrastructure to respond to the threat posed by biological weapons and emerging infectious
diseases. The Regional Centers for Excellence in Biodefense and Emerging Infectious Diseases Research
(RCE) program was a central component of the NIAID response to this threat, and was designed to "jumpstart"
research in biodefense within each of the 10 public health service regions of the U.S. In 2003, Washington
University in Saint Louis, Saint Louis University, the University of Missouri, Case Western Reserve University,
and the Midwest Research Institute received funding to establish the Midwest Regional Center for
Excellence in Biodefense and Emerging Infectious Diseases Research (MRCE) to support research on
biodefense in Region VII (Iowa, Kansas, Missouri and Nebraska) and parts of Ohio. The goals of the MRCE
were consonant with the goals of the RCE program: harness the best scientists in the region for discovery and
translational research designed to lead to the next generation of therapeutics, diagnostics and vaccines for
biological threats; provide training and career support to create a new generation of scientists working in this
field; establish core facilities to support researchers throughout the region; and develop an emergency
response plan that can rapidly bring to bear our scientific expertise and research capacity in the event of any
new biological threat to the region, the nation or the world.
Over the past 5 years the MRCE has made significant progress towards each of those goals, and we will
detail our accomplishments in subsequent sections. Given the scope of the program, and our aspirations, it is
not surprising that much remains to be done. While the fundamental goals of the MRCE remain the same, this
competitive renewal is built upon a research landscape that has been transformed by the RCE program. When
we prepared the MRCE proposal 5 years ago, there was strength in basic immunology and in microbial
pathogenesis research at the partner institutions, but relatively little was focused on the NIAID priority
pathogens. Research collaborations between the MRCE partner institutions did not exist on any substantive
level, and even intra-institutional collaborations in this research area were limited. There was no pipeline of
young scientists and clinicians interested in research careers in biodefense, and there were no established
biosafety training programs within the region.
The MRCE now coordinates and supports a vibrant, highly collaborative and closely integrated group that has
become the face of biodefense and emerging infectious diseases research throughout most of Region VII.
MRCE programs have created a pool of talented young investigators interested in biodefense and emerging
infectious diseases research. We have trained nearly 100 individuals to work safely at BSL3, and have
educated investigators and public health officials throughout the country. The MRCE has responded to three
separate regional emergencies, and has become an integral part of the disaster planning process for a
significant part of our region. We have more than doubled the number of participating institutions, and have
supported researchers from 10 different academic or industrial organizations. Most importantly, MRCE
investigators made seminal basic science and translational discoveries leading to new therapeutic targets for
West Nile, Dengue fever, pneumonic plague, Ebola, poxviruses, and a wide sector of RNA and DNA viruses
(section A.3). We also initiated a pioneering collaborative effort in pathogen discovery and assessment that led
to the recognition of 7 new viruses, one of which (WU polyomavirus), may be an important cause of respiratory
disease in children.
In our original application 5 years ago, we discussed how one could best assess the impact of a complex and
wide ranging program like the MRCE on the research effort in Region VII. We proposed then that the most
objective measure would be the change in extramural funding for biodefense and EID research in Region VII
(excluding MRCE funds) during the course of the MRCE program. Since 2002, (the baseline pre-MRCE year)
total extramural funding for biodefense and EID research (excluding MRCE and regional laboratory allocations)
in Region VII has increased more than 2.5 fold, with the greatest increases in 2006 and 2007 despite a flat NIH
budget. We believe the MRCE program has had a significant impact on Region VII and the nation, and are
committed to continuing this important work.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Admin Core - Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents
-
批准号:9893810
-
项目类别:
-
资助金额:$30.91万
-
财政年份:2020
-
负责人:HERBERT W VIRGIN
-
依托单位:
Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents
-
批准号:10364721
-
项目类别:
-
资助金额:$738.13万
-
财政年份:2019
-
负责人:HERBERT W VIRGIN
-
依托单位:
ConProject-001
-
批准号:10300358
-
项目类别:
-
资助金额:$7.39万
-
财政年份:2019
-
负责人:HERBERT W VIRGIN
-
依托单位:
Admin Core - Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents
-
批准号:10364722
-
项目类别:
-
资助金额:$63.72万
-
财政年份:2019
-
负责人:HERBERT W VIRGIN
-
依托单位:
Admin Core - Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents
-
批准号:10573255
-
项目类别:
-
资助金额:$41.04万
-
财政年份:2019
-
负责人:HERBERT W VIRGIN
-
依托单位:
Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents
-
批准号:9893808
-
项目类别:
-
资助金额:$738.13万
-
财政年份:2019
-
负责人:HERBERT W VIRGIN
-
依托单位:
Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents
-
批准号:10573254
-
项目类别:
-
资助金额:$738.13万
-
财政年份:2019
-
负责人:HERBERT W VIRGIN
-
依托单位:
Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents
-
批准号:8642370
-
项目类别:
-
资助金额:$637.76万
-
财政年份:2014
-
负责人:HERBERT W VIRGIN
-
依托单位:
Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents
-
批准号:9231379
-
项目类别:
-
资助金额:$664.42万
-
财政年份:2014
-
负责人:HERBERT W VIRGIN
-
依托单位:
Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents
-
批准号:9010908
-
项目类别:
-
资助金额:$669.77万
-
财政年份:2014
-
负责人:HERBERT W VIRGIN
-
依托单位:
Administrative Core
-
批准号:8234931
-
项目类别:
-
资助金额:$51.29万
-
财政年份:2011
-
负责人:HERBERT W VIRGIN
-
依托单位:
Developmental Projects Program
-
批准号:8234934
-
项目类别:
-
资助金额:$68.19万
-
财政年份:2011
-
负责人:HERBERT W VIRGIN
-
依托单位:
Novel interferon dependent innate antiviral mechanisms
-
批准号:8234936
-
项目类别:
-
资助金额:$33.82万
-
财政年份:2011
-
负责人:HERBERT W VIRGIN
-
依托单位:
IMMUNITY AND PATHOGENESIS OF A NOVEL NOROVIRUS
-
批准号:8095141
-
项目类别:
-
资助金额:$7.23万
-
财政年份:2010
-
负责人:HERBERT W VIRGIN
-
依托单位:
MRCE for Biodefense and Emerging Infectious Dieseases
-
批准号:7902736
-
项目类别:
-
资助金额:$191.13万
-
财政年份:2009
-
负责人:HERBERT W VIRGIN
-
依托单位:
Developmental Projects Program
-
批准号:7672128
-
项目类别:
-
资助金额:$53.44万
-
财政年份:2009
-
负责人:HERBERT W VIRGIN
-
依托单位:
Discovery and characterization of emerging, engineered and unrecognized pathogens
-
批准号:7672152
-
项目类别:
-
资助金额:$90.07万
-
财政年份:2009
-
负责人:HERBERT W VIRGIN
-
依托单位:
Novel interferon dependent innate antiviral mechanisms
-
批准号:7672132
-
项目类别:
-
资助金额:$33.44万
-
财政年份:2009
-
负责人:HERBERT W VIRGIN
-
依托单位:
Discovery of Novel Human Pathogens
-
批准号:7641583
-
项目类别:
-
资助金额:$37.02万
-
财政年份:2008
-
负责人:HERBERT W VIRGIN
-
依托单位:
Novel IFN - Dependent Innate Antiviral Mechanisms
-
批准号:7641550
-
项目类别:
-
资助金额:$45.08万
-
财政年份:2008
-
负责人:HERBERT W VIRGIN
-
依托单位:
海外基金